The stock of Editas Medicine Inc (EDIT) has seen a 56.10% increase in the past week, with a 43.28% gain in the past month, and a -23.81% decrease in the past quarter. The volatility ratio for the week is 39.84%, and the volatility levels for the past 30 days are at 15.55% for EDIT. The simple moving average for the past 20 days is 28.82% for EDIT’s stock, with a -44.70% simple moving average for the past 200 days.
Is It Worth Investing in Editas Medicine Inc (NASDAQ: EDIT) Right Now?
The 36-month beta value for EDIT is at 1.96. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 9 as “hold,” and 0 as “sell.”
The public float for EDIT is 81.78M, and currently, shorts hold a 20.90% of that float. The average trading volume for EDIT on February 24, 2025 was 3.85M shares.
EDIT) stock’s latest price update
The stock of Editas Medicine Inc (NASDAQ: EDIT) has decreased by -6.80 when compared to last closing price of 2.06. Despite this, the company has experienced a 56.10% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-01-17 that Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despite market pessimism. Intellia’s advanced clinical-stage programs and a clear path to market support a speculative “Buy” rating for long-term NTLA investors with a high-risk tolerance. Editas’ in vivo CRISPR pipeline is still in the early stages, leading to a temporary “Hold” rating for EDIT stock until more clarity on targeted indications and clinical results is provided.
Analysts’ Opinion of EDIT
Stifel gave a rating of “Hold” to EDIT, setting the target price at $3 in the report published on December 13th of the previous year.
EDIT Trading at 33.53% from the 50-Day Moving Average
After a stumble in the market that brought EDIT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.42% of loss for the given period.
Volatility was left at 15.55%, however, over the last 30 days, the volatility rate increased by 39.84%, as shares surge +36.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.28% lower at present.
During the last 5 trading sessions, EDIT rose by +56.10%, which changed the moving average for the period of 200-days by -66.14% in comparison to the 20-day moving average, which settled at $1.4905. In addition, Editas Medicine Inc saw 51.18% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EDIT starting from O’Neill Gilmore Neil, who sale 1,618 shares at the price of $2.08 back on Dec 03 ’24. After this action, O’Neill Gilmore Neil now owns 312,106 shares of Editas Medicine Inc, valued at $3,361 using the latest closing price.
Mei Baisong, the EVP, CHIEF MEDICAL OFFICER of Editas Medicine Inc, sale 541 shares at $2.08 during a trade that took place back on Dec 03 ’24, which means that Mei Baisong is holding 133,354 shares at $1,124 based on the most recent closing price.
Stock Fundamentals for EDIT
Current profitability levels for the company are sitting at:
- -3.7 for the present operating margin
- 0.9 for the gross margin
The net margin for Editas Medicine Inc stands at -3.41. The total capital return value is set at -0.9. Equity return is now at value -78.56, with -50.61 for asset returns.
Based on Editas Medicine Inc (EDIT), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -4.72. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -65.88.
Currently, EBITDA for the company is -163.12 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 1.64. The receivables turnover for the company is 490.14for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.75.
Conclusion
In conclusion, Editas Medicine Inc (EDIT) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
